Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Hypoparathyroidism Market Value Growth And Long-Term Outlook
The hypoparathyroidism market has shown robust expansion in recent years. Its valuation is predicted to rise from $1.03 billion in 2025 to $1.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.6%. The historical surge in this market can be attributed to factors such as complications arising from thyroid surgery, various cases of calcium deficiency, increased awareness surrounding rare diseases, specialized endocrine services provided by hospitals, and the accessibility of hormone replacement treatments.
The hypoparathyroidism market size is predicted to show robust expansion over the next few years. It is expected to achieve a valuation of $1.54 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period stems from progress in recombinant therapies, better diagnosis of rare diseases, patient adherence initiatives, the spread of specialty clinics, and the adoption of precision endocrinology. Significant developments in the forecast period are set to include a rise in the diagnosis of rare endocrine disorders, the increasing application of recombinant parathyroid hormones, the broader availability of long-term calcium management treatments, enhanced awareness of post-surgical complications, and the creation of supplementary supportive treatments.
Get A Free Sample Report With In-Depth Market Insights:
Hypoparathyroidism Market Growth Drivers: What’s Behind The Acceleration?
The anticipated increase in thyroid cancer cases is projected to fuel the expansion of the hypoparathyroidism market in the coming years. Thyroid cancer is defined as a condition where abnormal cells develop within the thyroid gland, often forming a lump in the neck. The rising occurrence of thyroid cancer is linked to advancements in diagnostic imaging technologies, which enable earlier and more frequent identification of small, asymptomatic thyroid nodules. Thyroid cancer accelerates hypoparathyroidism by increasing the necessity for thyroid surgeries, procedures that can inadvertently damage the parathyroid glands. This leads to an imbalance of calcium and a chronic hormone deficiency, thereby driving the demand for long-term disease management solutions. For instance, in May 2024, according to the American Cancer Society, a US-based non-profit organization, the count of new thyroid cancer cases reached 44,020 in 2025, showing an increase from 43,720 in 2023. Therefore, the growing number of thyroid cancer cases is propelling the growth of the hypoparathyroidism market.
Hypoparathyroidism Market Segment Analysis And Revenue Potential
The hypoparathyroidism market covered in this report is segmented –
1) By Treatment: Hormone Replacement Therapy, Adjunctive Therapies
2) By Type: Hormone Replacement Therapy, Calcium And Vitamin D Supplements, Emerging Therapies
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End User: Hospitals, Specialty Clinics, Homecare Settings
Subsegments:
1) By Hormone Replacement Therapy: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues, Calcimimetics, Calcium And Vitamin D Supplements
2) By Adjunctive Therapies: Magnesium Supplements, Phosphate Binders, Other Supportive Therapies
Hypoparathyroidism Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the hypoparathyroidism market are concentrating on creating technologically advanced products, such as those based on transition technology, to enhance treatment efficacy and improve patient outcomes. TransCon technology-based products are therapeutics developed using TransCon (Transient Conjugation) technology, a proprietary platform engineered to optimize drug delivery. For example, in January 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched YORVIPATH (palopegteriparatide), its second TransCon technology-based product, in Germany and Austria for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is a once-daily prodrug of parathyroid hormone (PTH 1-34) designed to maintain physiological PTH levels over 24 hours, addressing the underlying hormone deficiency in chronic hypoparathyroidism.
Hypoparathyroidism Market Key Players Shaping Industry Direction
Major companies operating in the hypoparathyroidism market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc , Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited , Lupin Limited, Torrent Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., BridgeBio Pharma Inc., Ascendis Pharma A/S, Extend Biosciences Inc., Entera Bio Ltd.
View The Full Hypoparathyroidism Market Report:
Hypoparathyroidism Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the hypoparathyroidism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypoparathyroidism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
